Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-Current Assets (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Non-Current Assets for 7 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 18.44% to $8.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.4 million, a 26.64% decrease, with the full-year FY2025 number at $8.8 million, down 18.44% from a year prior.
  • Non-Current Assets was $8.8 million for Q4 2025 at Fulcrum Therapeutics, down from $9.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $21.0 million in Q2 2022 to a low of $8.8 million in Q4 2025.
  • A 5-year average of $13.7 million and a median of $12.7 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 124.02% in 2022, then tumbled 32.25% in 2025.
  • Fulcrum Therapeutics' Non-Current Assets stood at $9.0 million in 2021, then soared by 112.91% to $19.2 million in 2022, then decreased by 19.15% to $15.5 million in 2023, then plummeted by 30.33% to $10.8 million in 2024, then decreased by 18.44% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Non-Current Assets are $8.8 million (Q4 2025), $9.0 million (Q3 2025), and $9.5 million (Q2 2025).